logo
Why medical research needs to be more inclusive — and what we're doing about it

Why medical research needs to be more inclusive — and what we're doing about it

Irish Examiner15-07-2025
The covid-19 pandemic changed many aspects of our lives. One of the most notable shifts in healthcare has been a much greater awareness of how health outcomes differ across different communities — and how our medical research has not always kept up.
Take, for example, the pulse oximeter — a device usually clipped to a finger and used to monitor oxygen levels in patients. As low oxygen levels were key concern for those with severe covid, pulse oximeters were used a lot. They were also found to be significantly less accurate for people with darker skin, often overestimating oxygen levels and potentially delaying urgent treatment.
The pulse oximeter is a poster child for the dangerous consequences of not including a diverse range of people in health research. Not only do individuals receive poorer care, but care is also unequal, and trust in the healthcare systems erodes.
This is part of a wider issue. For decades, randomised trials — the gold standard for testing new treatments — have disproportionately involved white, male, and relatively healthy participants. That's despite the fact many health conditions affect other groups in more severe or complex ways. Groups that are frequently left out include women, ethnic minorities, LGBTQ+ individuals, older adults, pregnant or lactating females and people with disabilities.
The pulse oximeter is a poster child for the dangerous consequences of not including a diverse range of people in health research.
These are called under-served groups — populations under-represented in research despite often carrying a higher burden of disease. Women, for example, have been under-represented in many trials for decades, resulting in women having more side-effects because of biological differences between how male and female bodies absorb some medicines.
Take heart disease as an example. Women are just as likely to have a heart attack as men, but women are more likely to die from one. Women are also more likely to suffer from autoimmune diseases, but research often fails to examine womne separately, excludes them or doesn't include them in sufficient numbers to say anything meaningful about potential differences. Research conducted with and on both sexes can help reduce these disparities.
This is the motivation behind SENSITISE, a new EU-funded project in UCC, with partner institutes the University of Aberdeen, UK, Masaryk University, Czech Republic and ECRIN (European Clinical Research Infrastructure Network) France. SENSITISE — short for inclusive clinical trials: training and education to increase the involvement of under-served groups — is about creating real, practical change in how we educate the next generation of trialists.
Supported by the EU Erasmus+ programme until 2026, SENSITISE includes a 12-week, open-access curriculum available online, a manual for teachers, in-person workshops for those working in clinical trials, and translations into multiple languages to ensure broad accessibility. Our audience includes not just students and researchers, but also public and patient contributors, because inclusion starts with listening to the people affected.
Our goal is simple but urgent: to make inclusive health research the norm, not the exception. This political backdrop makes the work of SENSITISE even more urgent. While parts of the world move backwards on inclusion, we are pushing forward — developing tools to help the next generation of researchers build better, fairer trials from the ground up.
In the United States, a dramatic shift in policy is under way. President Donald Trump recently issued executive orders banning diversity, equity, and inclusion (DEI) initiatives across the federal government, including in healthcare and medical research.
Frances Shiely: If trials are designed only for the majority, then under-served communities will continue to receive second-rate care, or no care at all.
The orders eliminate DEI officers, revoke protections for LGBTQ+ individuals, and direct federal agencies to redefine gender strictly in biological terms — an approach that risks excluding entire communities from equitable access to healthcare and research participation.
The withdrawal of women's reproductive rights and subsequently, women's rights, along with banning the word ''women'' from all governmental health websites is unimaginable to us here in Europe.
Even before the Trump administration came to power in January 2025, the United States had work to do to improve women's health. In 2022, maternal mortality, deaths due to complications from pregnancy or childbirth, was 22.3/100,000 live births, more than double and sometimes triple the rate for most high-income countries (Ireland is 8.3/100,000; UK is 13.6/100,000; Australia and Germany, 3.5/100,000; Netherlands 2.8/100,000).
But this hides the health inequities. For black women in the US, the maternal mortality in 2022 was 49.5/100,000 compared to 19.0/100,000 for white women. According to figures from the World Health Organization, maternal mortality for black women living in the US is higher than overall mortality in many countries, including Argentina, Egypt and Mongolia. This is not only a US issue: maternal mortality for black women in the UK is 35.1/100,000. There is work to do in Europe too.
However, the policies of the Trump administration will widen these gaps, not narrow them. The impact of this disruption of science and the subsequent health outcomes will be profound and would have seemed almost unimaginable only a few months ago. Left unchallenged, the threat of these policies spreading increases.
If trials do not include the people who have most to gain from improved treatment, inequity in health outcomes becomes a persistent feature of the healthcare system. This is bad science, and bad for society. Inclusive research isn't just about who gets invited to participate — it's about who benefits from science.
If trials are designed only for the majority, then under-served communities will continue to receive second-rate care, or no care at all. The result? Worse outcomes; widening inequality; a healthcare system that serves some, but not all.
We are at a crossroads. One path leads to a narrower, exclusionary science that leaves people behind. The other leads to research that reflects the real world and delivers better outcomes for all.
At UCC, we're proud to be leading the way through SENSITISE, equipping the next generation to build trials that are inclusive, ethical and effective. Because inclusive research doesn't just change science, it changes lives.
Frances Shiely is professor of clinical trials, HRB Clinical Research Facility and School of Public Health, at University College Cork
Read More
Have we learned any lessons after Grace?
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Asthma Society urges action in Budget to address affordability of medication
Asthma Society urges action in Budget to address affordability of medication

Irish Daily Mirror

time27 minutes ago

  • Irish Daily Mirror

Asthma Society urges action in Budget to address affordability of medication

A quarter of asthma patients have skipped essential medication due to financial pressure in the last three months, according to the Asthma Society of Ireland. Ireland has one of the highest asthma rates globally, with 450,000 people affected — the fourth highest per capita rate in the world. Asthma imposes a heavy financial burden, with some medications costing up to €80 a month, and mortality and hospitalisation rates remain significantly higher than EU averages, with half of those with asthma showing signs of poor asthma control. New survey data from the organisation shows that 24 per cent of respondents reported going without asthma medication at least once in the past three months because they couldn't afford it. The Asthma Society is now urging the government to take decisive action in Budget 2026 to address the affordability crisis impacting people with asthma. Further data shows more than half (56 per cent) experienced difficulties making ends meet, with a quarter of respondents (25 per cent) going into arrears on mortgage or rental payments, utility bills, hire purchase or other loan payments at least once over the previous 12 months. Launching its Pre-Budget Submission 2026, Backing Every Breath, Building Better Care, the Asthma Society of Ireland is seeking urgent investment in three priority areas — affordable medication, expanded asthma care services and staffing, and targeted home energy upgrades to improve indoor air quality for people with asthma. 'The survey finding that so many people with asthma are having it difficult to make ends meet is, unfortunately, a surprise to no one in the asthma community,' said Eilís Ní Chaithnía, CEO of the Asthma Society of Ireland. 'Asthma imposes a heavy financial burden, with some medications costing up to €80 a month. 'With a combination of targeted investment and taxation measures, we can bring asthma under control, reduce exacerbations, hospitalisations and preventable deaths, and improve quality of life for hundreds of thousands of people in Ireland. But it will also require political will. 'An overwhelming majority (96 per cent) of those who responded to our survey said that they want the Government to take action in the upcoming Budget to reduce the financial burden of asthma on households. 'Simply put, they need this Government to make sure that they can take their asthma medications as prescribed, access specialist and diagnostic care when they need it, and live in homes that don't make them sick,' Ms Ní Chaithnía continued. Case Study Emily Smyth, 33, was diagnosed with severe asthma in her early 20s. Originally from Ballsbridge in Dublin, Emily experienced an episode of acute shortness of breath, chest tightness and coughing. A GP confirmed it was an asthma attack and referred her to a respiratory consultant. 'Today I am on biologic therapy, two daily inhalers and regular antibiotics,' Emily said. She believes that patients have enough to cope with, without adding the unnecessary worry of not being able to afford medication: 'Managing asthma can be difficult and it can impact your life in so many ways,' said Emily. 'Medications enable us to manage symptoms and to live our lives. That's why it's so vital that the cost of treatment be addressed. 'Over 60 per cent of people in the Asthma Society's survey supported universal subsidisation of asthma medications, something I completely agree with," Emily said. 'As a healthcare professional myself, I'm also passionate about the need for specialist care for asthma. 'I'm extremely lucky to be under the wing of a severe asthma clinic team and the care that I have received has been truly incredible and has transformed my asthma management. An inhaler used for treating asthma (stock image) (Image: PA) 'Knowing that you have a team supporting you, who will ensure that you get the highest standard of care and specialist education is so important. 'However, access should not depend on where you live or be a 'postcode lottery'. 'Expanding specialist and diagnostic care would significantly improve the lives of people with asthma,' said Emily. Key Budget Asks The submission includes detailed costings and proposals to: Phase in subsidisation of asthma medication, prioritising combination and preventer inhalers (€14 million in Budget 2026). Reduce the Drugs Payment Scheme threshold by €8 and abolish prescription charges for medical card holders (combined cost of €84.5 million). Fund a national Severe Asthma Registry (€500,000), recruit an Advanced Nurse Practitioner to every severe asthma clinic and reopen unfilled posts for Respiratory Physiologists around the country. Expand the Warmer Homes Scheme, to provide free home energy upgrades for people with chronic respiratory conditions at risk of energy poverty (€29.5 million). Invest in primary prevention through smoking cessation programmes (€29.05 million) and targeted vaccination. For more information on the supports and services offered by the Asthma Society of Ireland, visit or call the Asthma Adviceline to speak to an asthma specialist nurse or physio on Freefone 1800 44 54 64 (Monday-Friday, 9am-5pm). Subscribe to our newsletter for the latest news from the Irish Mirror direct to your inbox: Sign up here. The Irish Mirror's Crime Writers Michael O'Toole and Paul Healy are writing a new weekly newsletter called Crime Ireland. Click here to sign up and get it delivered to your inbox every week

MSD won't close Irish sites as part of $3bn cutbacks
MSD won't close Irish sites as part of $3bn cutbacks

Irish Examiner

time10 hours ago

  • Irish Examiner

MSD won't close Irish sites as part of $3bn cutbacks

Pharmaceutical giant MSD is slashing $3bn (€2.59bn) from its annual spending as part of global job cut but said it will not be closing any of its Irish sites. MSD yesterday announced a global cost-cutting exercise as it prepares for generic competition to its Irish-manufactured cancer drug Keytruda, the world's best-selling medicine, which is predominantly made in Ireland. The company will cut administrative, sales and research jobs, with increased focus on the US market. It has not said where the roles will be lost or if any Irish workers will be among those affected. However, a spokesperson told the Irish Examiner: "The restructuring announced today does not include site closures in Ireland." MSD employs more than 3,000 people at eight locations in Ireland. These include MSD Brinny in Co Cork specialising in development and manufacture of innovative novel vaccines and testing of immuno-oncology medicines; three facilities in Dublin (MSD Biotech, MSD Blackrock, and MSD Red Oak North); MSD Carlow; MSD Dunboyne in Co Meath; MSD Ballydine in Co Tipperary, the company's first Irish site; and MSD Dundalk, the former WuXi Vaccines sites acquired in January. The cost cuts will include $1.7bn (€1.47bn) in annual savings from the elimination of certain administrative, sales and R&D positions, MSD said. The company expects the restructuring to be completed by the end of 2027, the year before Keytruda's key patents expire and the drug faces US government price cuts. The company said it plans to reinvest the savings into developing new drugs and launching new products. EU-branded medicines will face 15% import tariffs under the new transatlantic trade deal agreed between the European bloc and the US at the weekend. Like many other pharmaceutical firms based in Ireland, MSD had stockpiled doses of Keytruda manufactured in Ireland, to protect itself from tariffs imposed in 2025. MSD previously disclosed plans to invest more than $9bn (€7.78bn) in US manufacturing over the next four years, part of an effort to make more of its medicines in the US. The company reiterated that it expects to spend $200m (€172m) on tariffs in 2025, a number that reflects levies already in place and doesn't account for future tariffs on pharmaceuticals.

US patients will pay cost of Donald Trump's 15 per cent tariffs on EU's pharma industry, Irish boss warns
US patients will pay cost of Donald Trump's 15 per cent tariffs on EU's pharma industry, Irish boss warns

The Irish Sun

time11 hours ago

  • The Irish Sun

US patients will pay cost of Donald Trump's 15 per cent tariffs on EU's pharma industry, Irish boss warns

AMERICAN patients will pay the cost of Donald Trump's 15 per cent tariffs on Europe's pharmaceutical industry, an Irish pharma company boss has warned. The Advertisement 2 CEO of Nutriband Gareth Sheridan fears the impact of the tariffs There Tanaiste Gareth Sheridan is CEO of Nutriband – a pharma company that specialises in patch technologies to enable safer use of pain medications and reduces the risk of addiction. The company is in a unique position in that they are based in the US and so will not face the 15 per cent tariffs. Advertisement Read more in News However, He told the Irish Sun: 'We won't be hugely impacted by the tariffs directly but we will be because we will be caught up in the industry impact. 'As a company that likes to describe ourselves as patient focused, we're very concerned at the effect that this will have on patients at the end of the day. 'Primarily that is where the fallout is going to be. To give you an example, 60 per cent of patients battling cancer in America today struggle with the cost of care as it is – and that's without a 15 per cent hike. Advertisement Most read in Irish News 'If you can imagine a 15 per cent hike in the cost of any sort of chemotherapies that is now being imported at a US level – that is very problematic. 'That's about two million people that are today barely making ends meet because of the cost of chemotherapy and you're going to have a 15 per cent price hike most likely unless the pharmaceutical companies absorb that cost.' US and EU agree landmark trade deal after months of talks, Donald Trump says The Irish pharma company boss believes that patients are being left behind in the discussion on tariffs as the majority of the discussion has been about the impact on jobs and the economy. He said: 'When it comes to negotiations and these discussions, ultimately people aren't statistics and patients need to be kept top of the narrative. Advertisement 'When we were talking bigger numbers and job losses and how its going to effect the economy and all those things – that's terrible. 'But ultimately when people are going to die - and they will die because they can't afford to live - I think that is a very dangerous precedent to set globally.' RESPONSE TEAM SET UP It comes as Business Minister Peter Burke established a Tariff Response Team to support Irish exporters who will be hit by the new 15 per cent tariffs. The trade team will give advice to businesses and manage new grants and funds that are being made available to assist Irish companies. Advertisement These include new market discover funds of up to €150,000 to help companies expand to new countries and €35,000 research grants to help firms mitigate the impact of the trade shake up. 2 The US clarified that pharma exports from the EU will be included in the tariffs Credit: Christopher Furlong/Pool via REUTERS

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store